Halozyme Therapeutics Files 8-K on Shareholder Vote and Exhibits
Ticker: HALO · Form: 8-K · Filed: Apr 26, 2024 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | 8-K |
| Filed Date | Apr 26, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, shareholder-vote
Related Tickers: HALO
TL;DR
HALO filed an 8-K for shareholder votes and financials - nothing major revealed yet.
AI Summary
On April 25, 2024, Halozyme Therapeutics, Inc. filed an 8-K to report on the submission of matters to a vote of security holders and financial statements and exhibits. The filing does not contain specific details on the nature of the vote or the financial information presented.
Why It Matters
This filing indicates that Halozyme Therapeutics is proceeding with matters requiring shareholder approval and is providing necessary financial documentation, which are standard corporate governance procedures.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for corporate governance matters and does not disclose any new material risks or significant events.
Key Players & Entities
- HALOZYME THERAPEUTICS, INC. (company) — Registrant
- April 25, 2024 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
- 12390 El Camino Real (address) — Principal Executive Offices
- San Diego (location) — City of Principal Executive Offices
- 92130 (zip_code) — Zip Code of Principal Executive Offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but does not specify what those matters are.
What financial statements and exhibits are included in this filing?
The filing indicates that financial statements and exhibits are included, but does not list their specific contents.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated April 25, 2024.
In which state was Halozyme Therapeutics, Inc. incorporated?
Halozyme Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Halozyme Therapeutics, Inc.?
The principal executive office is located at 12390 El Camino Real, San Diego, California 92130.
Filing Stats: 797 words · 3 min read · ~3 pages · Grade level 12.2 · Accepted 2024-04-26 16:22:23
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market
Filing Documents
- halo-20240425.htm (8-K) — 49KB
- exhibit31amendedandrestate.htm (EX-3.1) — 10KB
- halo-20240425_g1.jpg (GRAPHIC) — 15KB
- 0001159036-24-000031.txt ( ) — 212KB
- halo-20240425.xsd (EX-101.SCH) — 2KB
- halo-20240425_lab.xml (EX-101.LAB) — 21KB
- halo-20240425_pre.xml (EX-101.PRE) — 12KB
- halo-20240425_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On April 25, 2024, Halozyme Therapeutics, Inc. (the " Company " ) held its Annual Meeting of Stockholders. Of the 127,054,240 shares of the Company's common stock outstanding as of the record date, 115,681,780 shares were represented at the annual meeting. The stockholders considered four proposals at the meeting, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2024. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below. Proposal 1 : Election of two Class II directors to hold office for a three-year term expiring at the 2027 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified: Names Votes For Votes Against Abstain Broker Non-Votes Barbara Duncan 90,120,424 15,016,536 161,704 10,383,116 Mahesh Krishnan, M.D. 103,968,663 1,164,017 165,984 10,383,116 Each of the foregoing candidates was elected and each received affirmative votes from more than a majority of the outstanding shares. The Company's Board of Directors (the " Board " ) has appointed Dr. Krishnan to serve on the Board's Nominating and Corporate Governance Committee. Proposal 2 : The advisory vote on the compensation of the Company's named executive officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 102,860,435 2,190,603 247,626 10,383,116 The foregoing proposal was approved. Proposal 3: The vote on a proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 91,512,252 13,612,616 173,796 10,383,116 The foregoing proposal was approved. On April 25, 2024, the Company filed with the Secretary
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Amended and Restated Certificate of Incorporation of Halozyme Therapeutics, Inc. 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HALOZYME THERAPEUTICS, INC. (Registrant) April 26, 2024 /s/ Mark Snyder Mark Snyder Senior Vice President, General Counsel and Corporate Secretary